Related Experiment Video

Updated: Apr 19, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

8.2K

Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab

Niklas Krupka1, Daniel C Baumgart1

  • 1Division of Gastroenterology and Hepatology, Department of Medicine, Charité Medical School, Humboldt-University of Berlin, Berlin, Germany.

Drug Design, Development and Therapy
|January 2, 2015
PubMed

Insights

New therapies are needed for inflammatory bowel diseases like Crohn's disease. Vedolizumab, an anti-α4β7 therapy, shows promise in targeting leukocyte recruitment for future treatment strategies.

Area of Science:

  • Gastroenterology and immunology
  • Inflammatory bowel disease (IBD) research
  • Biologic therapy development

Background:

  • Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases.
  • Current treatments targeting tumor necrosis factor alpha have limitations, including non-response and side effects.
  • There is a significant unmet need for novel therapeutic strategies in IBD management.

Purpose of the Study:

  • To review clinical trial results of vedolizumab, a novel biologic agent.
  • To evaluate the impact of vedolizumab on the management of inflammatory bowel disease.
  • To highlight vedolizumab as a potential therapeutic target for leukocyte recruitment in chronic inflammation.

Main Methods:

  • Review of clinical trial data for vedolizumab (anti-α4β7).
  • Analysis of vedolizumab's efficacy and safety in IBD patients.
  • Discussion of vedolizumab's mechanism of action targeting leukocyte trafficking.

Main Results:

  • Vedolizumab targets the α4β7 integrin, inhibiting leukocyte recruitment to the gut.
  • Clinical trials demonstrate vedolizumab's potential in managing inflammatory bowel disease.
  • The drug offers an alternative therapeutic option for patients with unmet needs.

Conclusions:

  • Vedolizumab represents a promising novel therapeutic strategy for inflammatory bowel disease.
  • Targeting leukocyte recruitment with vedolizumab addresses limitations of existing therapies.
  • Further research and clinical application of vedolizumab are expected to impact future IBD management.
Keywords:
Crohn’s diseaseLDP-02MLN-02MLN0002anti-α4β7ulcerative colitisvedolizumab

More Related Videos

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

624

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
821
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
738
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows...
4
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
686
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The...
1